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Purpose. Tissue engineering seeks to replace and regrow damaged or diseased tissues and organs from
either cells resident in the surrounding tissue or cells transplanted to the tissue site. The purpose of this
review is to present the application of polymeric delivery systems for growth factor delivery in tissue
engineering.
Methods. Growth factors direct the phenotype of both differentiated and stem cells, and methods used
to deliver these molecules include the development of systems to deliver the protein itself, genes
encoding the factor, or cells secreting the factor.
Results. Results in animal models and clinical trials indicate that these approaches may be successfully
used to promote the regeneration of numerous tissue types.
Conclusions. Controlling the dose, location, and duration of these factors through polymeric delivery
strategies will dictate their utility in tissue regeneration.
KEY WORDS: regeneration; drug delivery; gene delivery; cell transplantation.
INTRODUCTION
The rapidly developing field of tissue engineering aims to
replace or facilitate the regrowth of damaged or diseased tis-
sue by applying combinations of biomaterials, cells, and bio-
active molecules. Tissue engineering seeks to fill the void
created by the growing disparity between the number of tis-
sues and organs needed and the numbers available for trans-
plantation (1). Transplantation of tissues from autogeneic
(from the host), allogeneic (from the same species), and xe-
nogeneic (from a different species) sources has been a major
strategy in tissue repair, but the limited availability of tissue
and the issues associated with immunogenicity and disease
transmission have fueled the search for a better source for
tissue replacement.
Various tissues in the body contain cells competent to
regenerate after injury or destruction, but the regenerative
capability varies widely with cell type and the circumstances
of injury. Actively renewing cells of certain tissues (e.g., skin,
bone marrow and intestinal mucosa) are competent for com-
plete regrowth, but this ability of the cells is dependent on a
number of factors, such as the size of defect, age of individual,
and specific cause of defect. In contrast, cells in other tissues
(e.g., heart muscle and nerve) are static and do not typically
regenerate lost tissue structure or function. In either case,
transplantation of desired cell populations may increase the
rate or extent of new tissue formation. In all of these situa-
tions, the local presence of growth factors capable of instruct-
ing both cells resident in the tissue and transplanted cells will
likely be key to the ultimate success of the regenerative pro-
cess.
Although growth factors clearly play important roles in
harnessing and controlling cellular functions in tissue regen-
eration, the appropriate mode for making these factors avail-
able at the desired site remains unclear. Bolus delivery of
these molecules is technically simple, but the subsequent dis-
tribution of the factors throughout the body and their rapid
degradation may lead to undesirable systemic effects and tox-
icity, and an insufficient local concentration for the required
time frame, respectively. The use of polymeric vehicles to
locally deliver the factors in various formats provides a
method of controlled, localized delivery for the desired time
frame. This review focuses on the application of inductive
large peptide growth factors through polymeric delivery sys-
tems for tissue-engineering therapies for wound healing, bone
regeneration, and angiogenesis. Reviews highlighting other
tissues (e.g., neural, Ref. 2; skeletal muscle, Ref. 3) are avail-
able from other sources. Short overviews of growth factor
biology and the design criteria for delivery vehicles these mol-
ecules precede descriptions of specific applications.
GROWTH FACTORS
Growth factors are secreted by a wide range of cell types
to transmit signals that activate specific developmental pro-
grams controlling cell migration, differentiation, and prolif-
eration (Fig. 1). Cell signaling occurs through growth factor
binding to its receptor on the cell surface. The signal is trans-
ferred through the membrane receptor and amplified, often
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through phosphorylation of secondary messengers within the
target cell, to ultimately modify gene expression. Growth fac-
tors act in a concentration- and time-dependent manner, of-
ten requiring minute quantities to elicit biologic activity, and
their action can depend on a variety of factors, including cell
location within a tissue structure and cell cycle state. Eluci-
dation of differentiation and proliferation pathways for vari-
ous tissues has revealed that they are complex events involv-
ing a cascade or a network of multiple growth factors (4).
Regulation of growth factor activity occurs on several
levels, from controlled gene expression to degradation. Tran-
scriptional activation of growth factors and receptor genes
create mRNAs that are unstable, yielding brief synthesis of
limited peptide quantities (4). Growth factors are released by
cells for immediate signaling or are embedded in the extra-
cellular matrix (ECM) and released as the ECM degrades
through controlled proteolysis. Sequestering of growth fac-
tors in the ECM allows growth factor stabilization and pro-
vides physical cues for cells through compartmentalization or
spatial presentation of these factors. Controlled secretion of
factors and their release from the ECM is balanced by extra-
cellular degradation. Altogether these processes contribute to
the existence of a biologic growth factor delivery system that
is responsive and dynamic, changing according to specific cel-
lular requirements and processes.
DESIGN CRITERIA FOR GROWTH FACTOR
DELIVERY SYSTEMS
There are several important considerations in the design
of a delivery system for growth factors used to regenerate or
engineer tissues. First, given the quantity and complex actions
of growth factors, it is essential to identify the key growth
factor or factors to deliver for a particular tissue application
based on an understanding of biologic developmental pro-
cesses (see Table I for a list of commonly used growth factors
and their known activities). The application of growth factors
as therapeutic molecules has focused on those that are best
characterized and available in large quantities as recombinant
proteins.
Second, the mode of factor delivery must target the de-
sired cell population and minimize signal propagation to non-
target tissues and cells. The earliest reported applications of
growth factors as therapeutic agents involved intravenous in-
jection, but this delivery method is not localized to the target
tissue and is also ineffective because of the growth factors’
short half-lives. Although very small quantities (picograms to
nanograms) of growth factor are necessary to generate a cel-
lular response, growth factors are rapidly degraded once se-
creted. The biologic half-lives of platelet-derived growth fac-
tor (PDGF), basic fibroblast growth factor (bFGF or FGF-2),
and vascular endothelial growth factor (VEGF), for example,
Fig. 1. Growth factor binding to a cell surface receptor can elicit
different types of responses to regenerate tissue in a defect site. A,
Chemotactic responses to growth factor binding result in cell migra-
tion into a defect site. B, Cell differentiation can occur to provide the
needed cell population. C, Proliferation of cells within the site fill the
tissue defect.
Table I. A List of Growth Factors Commonly Used in Tissue Engineering
Growth factor Abbreviation
Molecular
weight (kDa) Known activities
Representative supplier
of rH growth factor
Epidermal growth
factor
EGF 6.2 Proliferation of epithelial, mesenchymal,
and fibroblast cells
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are 2 (5), 3 (6), and 50 min (7) respectively, when intrave-
nously injected. Direct therapeutic application of growth fac-
tors therefore requires substantial systemic doses at levels
that can generate undesired effects (8). These issues have
motivated the development of controlled delivery systems
that allow the sustained and localized delivery of small
amounts of these factors to the target cell population and
tissue site.
Third, the controlled delivery of factors requires a rela-
tively long-term maintenance of biologic activity within the
system. These systems function in many ways as an artificial
ECM to stabilize embedded or encapsulated growth factor.
This is often challenging because processes used to formulate
protein delivery constructs may denature or deactivate the
protein. Therefore, methods of fabrication that do not require
harsh solvents or high temperatures are often desirable if the
protein itself is used as the regenerative agent.
Finally, the release profile of the growth factor from the
system should be controlled temporally and spatially to be
appropriate for a specific tissue injury or disease. Tissues
must frequently be exposed to these factors for relatively long
time-frames (e.g., days to weeks) to obtain the desired effects.
Spatial localization of the signaling molecule may enable one
to control not only the extent of tissue formation, but also the
pattern of tissue formation.
A variety of polymeric delivery systems have been de-
signed to meet the design criteria for growth factor delivery
(Fig. 2). The factors themselves may be directly incorporated
into the polymer (Fig. 3A). Alternatively, plasmid DNA en-
coding the factor may be immobilized within the polymer,
allowing the local production of the factor by cells that take
up and express this DNA following implantation of the sys-
tem at the desired tissue site (Fig. 3B). Finally, the polymer
system may be used to transplant cells that secrete the desired
factor (Fig. 3C). These differing approaches to factor delivery
are described in the following sections and a summary of
tissues regenerated using growth factor delivery strategies is
provided in Table II.
PROTEIN DELIVERY SYSTEMS
Polymeric systems can be successfully used to administer
small doses of factors at defined dose rates directly to target
cells. Polymeric delivery systems composed of various natural
and synthetic biocompatible polymers can provide controlled
growth factor delivery by differing mechanisms. One techni-
cally simple polymer delivery system involved the mixing of
growth factors in an albumin gel (9), creating one of the first
reported investigations of growth factor delivery in a polymer
matrix. Since then, the number and complexity of available
constructs has increased to include hydrogels, microspheres,
and three-dimensional, porous scaffolds (Fig. 2). The release
profiles of molecules from such carriers can be controlled by
both factor diffusion and polymer degradation, the dose of
the factor loaded in the system, and the composition of the
polymer.
Both naturally derived and synthetic polymers have
found utility in growth factor delivery. Natural polymers and
their derivatives in the form of gels and sponges have been
used extensively as delivery vehicles. Collagen in particular is
a readily available ECM component that allows cell infiltra-
tion and remodeling, making it highly suitable for growth
factor delivery. Recombinant forms of collagen may circum-
vent issues of immunogenicity and disease transfer that can
occur with collagen extracted from animal sources. Biode-
gradable synthetic polymers are also very attractive for tissue
engineering applications because of their well-controlled,
reproducible chemical and physical properties. Homo- and
copolymers of lactide and glycolide have found numerous
applications in this field because of their wide use in a number
Fig. 2. Polymeric growth factor delivery vehicles may be processed
into various forms, including (A) microspheres, (B) porous scaffolds,
or (C) injectable gels. A and B are scanning electron microscopy
images taken of a typical PLG microsphere and a gas-foamed scaffold
respectively (images courtesy of Martin Peters).
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of medical devices (e.g., sutures) and degradation into natural
products (lactic and glycolic acid) that enter into metabolic
pathways. The physical properties of these polymers can be
readily altered by varying the ratio of lactide:glycolide, mo-
lecular weight, and crystallinity.
Wound Healing
Skin and wound healing was one of the first areas where
the therapeutic potential of growth factors was investigated
and the first area with a growth factor based pharmaceutical
product. The clinical need for wound healing is vast, ranging
from burn victims to patients with diabetes whose natural
wound repair mechanisms are impaired. Approximately 2
million people suffer burns each year, with 13,000 requiring
skin grafts, and diabetic foot ulcers affect over 800,000 people
each year. In this application area, growth factors have the
potential to reduce scarring and accelerate the healing pro-
cess driven by cells already present in tissue adjacent to the
wound site.
A number of factors have been identified that mediate
skin regeneration, including epidermal growth factor (EGF),
transforming growth factor- and - (TGF-, TGF-), and
PDGF (10). Both EGF and TGF- induce the proliferation
and differentiation of various epithelial cells both in vitro and
in vivo (11). PDGF is a mitogen and chemotactic agent of
fibroblasts and smooth muscle cells while stimulating macro-
phages to secrete other growth factors important for various
stages of the healing process. PDGF also stimulates the pro-
duction of several ECM molecules, including collagen and
fibronectin (12). TGF- is also involved in ECM deposition
and scarring in the natural progression of wound healing (13).
It will likely be critical to deliver these molecules in a local-
ized and controlled manner to achieve the desired biologic
response, while avoiding harmful side-effects (14).
Many studies have now documented the utility of local-
ized and sustained delivery of growth factors on wound heal-
ing. Natural polymers formulated into viscous gel suspensions
(9) or porous sponges (15) have been used to deliver these
factors while maintaining growth factor activity (16). Investi-
gations into delivery strategies using such polymeric carriers
have resulted in the first Food and Drug Administration-
approved growth factor system for tissue regeneration, Re-
granex, a topically applied gel for the treatment of diabetic
foot ulcers. This product is based on PDGF (0.01% recombi-
nant PDGF-BB), delivered in a carboxymethylcellulose-
based gel (17). More recently, delivery systems have inte-
grated growth factor release with existing wound healing aids
(18,19) to form enhanced wound healing systems. Modifying
biomaterials conventionally used for wound repair into
growth factor delivery systems may produce systems with sig-
nificant clinical utility.
Bone Regeneration
Approximately 2500 new cases of primary bone cancer
and 13,500 new cases of myeloma are diagnosed in the United
States each year. In addition, an estimated 200,000 bone
grafts are performed annually in the United States for bone
defects incurred from sports injuries or trauma. From these
numbers, it is evident that there is a great demand for thera-
pies to enhance bone regeneration. A primary goal of growth
factor delivery for bone tissue engineering is to accelerate
healing and enhance bone formation. Tissue-engineered
bone, whether intended to heal a fracture or to fill a critical-
sized defect, needs to not only be mechanically competent but
also be vascularized living tissue. Tissue-engineering ap-
proaches in this area have focused on osteoinductive or os-
teoconductive implant strategies. Osteoinduction uses the de-
livery of growth factors to enable the migration, proliferation,
and differentiation of bone-forming cells already present in
the body to form new bone. Osteoconductive materials pro-
vide an appropriate matrix, in the form of scaffolds that en-
courage cell infiltration and anchorage for guided osteogen-
esis to occur. Conductive materials may also reinforce the
mechanical stability of a defect site while remodeling occurs.
A large number of factors involved in bone formation
and remodeling have been identified, and members of the
TGF- superfamily clearly play an important role. TGF- is
involved in early stages of bone development, as well as bone
repair and remodeling after trauma, through its regulation of
Fig. 3. Three primary polymeric growth factor delivery strategies. A,
Growth factors are embedded within the polymer matrix and re-
leased. B, Genes encoding a growth factor are embedded within the
polymer matrix and released, followed by cellular uptake and expres-
sion of the gene to produce growth factor. C, Growth factor is re-
leased from cells seeded on the polymer matrix that secrete the fac-
tor.
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the proliferation and differentiation of mesenchymal precur-
sor cells (20). Delivery of TGF-1 through biodegradable
polymer microparticles increased the proliferation and differ-
entiation of marrow stromal cells toward osteoblasts (21),
indicating its potential in controlled release systems for bone
engineering. Of high interest is the group of bone morphoge-
netic proteins (BMPs), which are members of the TGF- su-
perfamily. BMP-2 through BMP-8 are osteogenic proteins
that play an important role in embryonic development, gen-
eration of the central nervous system, and tissue repair (22).
These polypeptides have also been indicated in both endo-
chondral (through a cartilage intermediate) and intramem-
branous (direct) bone formation. BMP-2, the first BMP to be
available in a highly purified recombinant form, has pleiotro-
pic functions, acting primarily as a differentiation factor for
bone and cartilage precursor cells toward mature osteocytes.
In a variety of preclinical models, BMP-2 has demonstrated
the ability to induce bone formation and heal bony defects, in
addition to improving the maturation and consolidation of
regenerated bone (23). Recombinant human BMP-7 and
BMP-2 are among the first growth factor based products
available for clinical use to treat patients afflicted with bone
diseases.
A large number of studies have been performed to de-
termine appropriate carriers for BMPs. Carriers composed of
collagen are popular for bone induction, as it is the major
nonmineral component of bone. Recombinant forms of col-
lagen have been used as carriers for BMP delivery for spine
fusion in humans (24). Synthetic polymeric systems using poly
(lactide-co-glycolide) (PLG) processed into porous scaffolds
(25) and capsules (26) have also been used for rhBMP-2 de-
livery to allow for greater control over the rate of BMP re-
lease. Injectable systems of polyethylene glycol hydrogels
(27) and PLG microspheres (28) delivering BMP-2 had
also promoted osteoblast differentiation and mineralization
in vitro, and ectopic bone formation in vivo.
The utilization of a conductive substrate to deliver an
inductive biomolecule may enhance bone regeneration due to
the combined effects of the carrier and factor. However,
many systems for osteogenic growth factor delivery are not
osteoconductive. Osteoconductive materials include hydroxy-
apatite (HAP), calcium phosphate, and a variety of ceramic
biomaterials. Integrated systems are currently being pursued,
and a recent example includes the use of mineralized poly-
meric scaffolds (29) for growth factor delivery. Osteoconduc-
tive materials have also been combined with collagen to form
porous resorbable BMP delivery systems for spine fusion
(30).
In addition to the complexity inherent to regenerating
the mineralized tissue component of bone, nerves and blood
vessels must also be integrated with this tissue for full func-
tionality. Vascularization in particular, is an essential compo-
nent of de novo bone formation and a high degree of vascu-
larity is present in natural bone. There is recent evidence
Table II. Polymeric Carriers Used to Deliver Various Growth Factors and the Type of
Tissue Regenerated
Growth factor Carrier Tissue regenerated Representative ref.
EGF Gelatin Dermis (19)
PET suture Tendon (18)
PVA sponge Dermis (15)
PDGF Chitosan-PLLA scaffold Craniofacial bone (63)
CMC gel Dermis (17)
Fibrin Ligament (64)
Porous HA Long bone (65)
TGF- Alginate Cartilage (66)
PLA Long bone (67)
CaP-titanium mesh Craniofacial bone (68)
Polyoxamer; PEO gel Dermis (69)
rhBMP-2 Collagen sponge Long bone (70)
Craniofacial bone (71)
HA-TCP granules Spinal bone (24)
HA-collagen Long bone (72)
PLA-DX-PEG Ectopic and hip bone (73)
rhBMP-7 HA Spinal bone (74)
Collagen-CMC Spinal bone (75)
Porous HA Craniofacial bone (76)
bFGF Chitosan Dermis (77)
Heparin-alginate Blood vessels (36)
EVAc microspheres Blood vessels (78)
Fibrin matrices Blood vessels (79)
VEGF PLG scaffold Blood vessels (37)
PLG scaffold Blood vessels (40)
PLG microspheres Blood vessels (80)
Fibrin mesh Blood vessels (81)
Abbreviations: PET, poly (ethylene terepthalate); PVA, polyvinyl alcohol; PLLA, poly(L-lactic acid);
CMC, carboxymethylcellulose; HA, hydroxyapatite; PLA, poly(D,L-lactic acid); CaP, calcium phos-
phate; PEO, poly (ethylene oxide); TCP, tricalcium phosphate; PEG, poly(ethylene glycol);
-DX-, -p-dioxanone-; EVAc, ethylene vinyl acetate; PLG, poly (lactide-co-glycolide).
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showing both bone and blood vessel formation can be trig-
gered in response to the same growth factor, VEGF (31). An
extensive network of blood vessels is a general requirement
for the formation of any functional large tissues or organs,
and this may require the combined delivery of multiple bone
inducing and angiogenic factors.
Angiogenesis
New blood vessel formation is a critical requirement in
many vascular diseases and in tissue engineering. Coronary
artery disease is a major health problem for over 12 million
Americans, resulting in 571,000 coronary artery bypass sur-
geries annually. An increasing number of patients with coro-
nary artery disease are not candidates for revascularization
through traditional surgical methods. Therapeutic angiogen-
esis, the formation of new blood vessels via branching from
existing vessels, holds great promise to aid this patient popu-
lation. In addition, the entire tissue engineering field is lim-
ited by the need for vascularity in large tissues and organs for
nutrient and waste transport. Strategies to promote new
blood vessel networks will be essential in virtually all engi-
neered tissues (32).
Because of the central importance of angiogenesis in dis-
ease processes such as cancer and wound healing, the molecu-
lar mechanisms underlying angiogenesis have been exten-
sively elucidated. Angiogenesis is the result of a multi-step,
sequential process beginning with endothelial cell activation
and migration to sprout neovessels and ending with mature
vessels surrounded by smooth muscle cells and pericytes (32).
Growth factors that play key roles in this process include
FGF, VEGF, PDGF, TGF-, and angiopoietins-1 and 2
(Ang-1 and 2). Among these, VEGF, Ang-1, and Ang-2 are
more endothelial cell-specific. bFGF and VEGF are heparin-
binding growth factors involved in the initiation of angiogen-
esis, and promote endothelial cell proliferation and migration.
PDGF-BB recruits smooth muscle cells and pericytes which,
along with TGF-, promote ECM deposition to stabilize
neovessels.
The identification of growth factors involved in angio-
genesis has led to their application in treating coronary artery
disease and other diseases involving tissue ischemia. Bolus
injections of solutions of growth factors have been investi-
gated as treatments for myocardial ischemia, with promising
results in animal models and small-scale clinical trials (33).
However, these delivery methods did not appear to have had
as significant of an effect in large clinical trials (34). These
latter results are likely related to the very short half-lives
(minutes to hours) of these factors in vivo. This limitation
could potentially be overcome by delivering extremely large
quantities of these factors in the same fashion, but this may
then lead to vessel formation at nontarget sites and elicit
harmful side-effects as a result of the presence of these potent
drugs throughout the body. Polymeric delivery vehicles have
therefore been pursued to allow for localized, controlled de-
livery of angiogenic factors to alleviate risks and obtain thera-
peutic benefit. Various types of polymeric materials have
been used for controlled release of bFGF and VEGF, includ-
ing alginate hydrogels, PLG microspheres, and porous PLG
scaffolds (35). Controlled release of bFGF encapsulated in
heparin-alginate pellets led to significant angiogenesis with
low systemic effects in patients undergoing bypass surgery
(36), but this approach did not alleviate operative risks. Fur-
ther information on clinical trials can be found in a recent
review on therapeutic angiogenesis (35).
Angiogenesis is also generally required for the integra-
tion of engineered tissues with surrounding host tissue. Insuf-
ficient blood vessels for nutrient delivery and waste removal
can result in the death of transplanted cells and limited tissue
regrowth. It has recently been demonstrated that promotion
of angiogenesis through the delivery of an angiogenic growth
factor enhances the engraftment of transplanted cells, includ-
ing endothelial cells (37), pancreatic islets (38), and hepato-
cytes (39).
Whether for tissue engineering or therapeutic applica-
tions, new blood vessels formed through the growth factor
delivery strategies described in this section are typically small
and lack pericyte incorporation. This finding suggests that
they may not be functional long-term and may be subject to
regression. A greater degree of control of the angiogenic cas-
cade may be required for the formation of functional, stable
vascular beds. It has recently been demonstrated that VEGF
delivery followed by PDGF resulted in larger, mature vessel
structures (40).
GENE DELIVERY AS AN ALTERNATIVE TO
PROTEIN DELIVERY
A significant limitation to direct protein delivery ap-
proaches is degradation of the molecules when exposed to the
in vivo environment, and limited stability even when encap-
sulated into a polymeric delivery vehicle. One approach to
potentially bypass these issues is to instead use localized gene
therapy to promote the production of the desired growth fac-
tor at a specific tissue site. This approach may have great
utility in application areas such as therapeutic angiogenesis
(41). The stability of DNA in various environmental condi-
tions typically encountered during production and processing
is much higher than proteins, and this approach can also lead
to a sustained delivery of the factor following single admin-
istration of the gene therapy.
To use gene delivery as a growth factor delivery strategy,
many complex challenges must be overcome. Low transfec-
tion efficiencies, inefficient gene targeting, low gene expres-
sion levels, and undesired gene integration into host DNA are
all challenges that underlie this growth factor delivery ap-
proach. It is also necessary to identify the target cell type most
appropriate for gene delivery to elicit the desired regenera-
tive effects.
The challenge of low transfection efficiencies has been
addressed with the use of gene guns and viral vectors. Deliv-
ery systems using gene guns inject cDNA directly into a site
and this approach has been used for delivery of genes encod-
ing PDGF-BB (42) and keratinocyte growth factor-1 (43) for
wound repair. However, this strategy depends on the pres-
ence of host cells able to take up and express the cDNA at
biologically relevant levels. There is also a technical limitation
due to the limited penetration depth, and this delivery
method may be best suited for surface wound healing. Ad-
enoviral gene delivery has been used to produce active
BMP-2 in skeletal muscle (44), and VEGF for therapeutic
angiogenesis (45). Concerns regarding the use of adenoviral
and lentiviral vehicles are the issues of virus safety, immuno-
genicity, and long term effects in vivo, as demonstrated by
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outcomes noted in recent adenoviral gene therapy trials (46).
Therefore, polymeric gene delivery vectors are being actively
pursued as alternatives to viral vectors.
Polymeric gene delivery vehicles have the potential to
effectively and safely deliver growth factor genes to target
cells. Direct DNA delivery through a polymeric vehicle (47)
may circumvent the issue of immune toxicity, and the use of
plasmid DNA addresses the issue of adverse effects resulting
from integration with host DNA. Polymeric gene delivery
vehicles include collagen (48) and PLGA (47,49). However,
DNA delivered in this manner is usually taken up by the cell
through nonspecific endocytosis, which can be inefficient and
unpredictable, with much of the DNA degraded in lysosomes.
Cationic polymer and lipid DNA condensates have also been
investigated for nonviral gene delivery (50). The delivery of
DNA condensates with polymer scaffolds may greatly en-
hance transfection efficiency and lead to stable gene expres-
sion over a longer period in vivo than delivery via other poly-
meric delivery vectors.
CELL TRANSPLANTATION
A third approach for delivery of growth factors in tissue
regeneration involves transplanting cells that synthesize and
secrete the desired growth factor. Autologous cells may be
used in this approach via the isolation of a small number of
differentiated adult cells or stem cells, followed by in vitro
expansion to produce an appropriate supply (Fig. 4). The cells
may naturally secrete or be genetically modified in vitro to
overexpress the factor, either transiently or permanently (Fig.
4). This approach may be particularly appropriate to deliver
growth factors that act by paracrine or juxtacrine mecha-
nisms. Appropriate carriers are required for transplanted cells in
order to localize their production of the factors, and polymeric
systems similar to those developed for protein delivery have
been used. These include collagen (51), peptide modified hy-
drogels (52), and biodegradable porous scaffolds (37,53).
Transplantation of cells that naturally secrete the desired
growth factor is one strategy to deliver biologically active
protein. One of the first large-scale applications of cell trans-
plantation arose in wound care, where sheets of cultured ke-
ratinocytes and fibroblasts were combined with wound dress-
ing materials to form cultured skin substitutes (54). Although
this approach uses transplanted cells to regenerate tissue, cul-
tured skin substitutes may also work via natural secretion of
growth factors from the cultured skin layer to the host wound
area. Cotransplantation of multiple cell types may mutually
induce differentiation and proliferation toward a desired tis-
sue type, through cell mediated growth factor signaling (52).
In addition, cells may provide responsive delivery systems
able to provide multiple factors. Human mesenchymal stem
cells can produce a number of growth factors, including bFGF
and VEGF, in response to changing culture conditions (55)
and transplantation of these cells may naturally provide the
appropriate growth factors needed to the host environment.
However, natural growth factor secreting cells often produce
the factors at low levels since they may not normally activate
the desired cellular processes.
Genetically modified cells are potentially able to provide
a stable source of growth factor at a level that is sufficient to
elicit a biologic response. For example, cultured dermal fibro-
blasts have been transduced to express PDGF and the modi-
fied cells were transplanted onto PGA scaffolds to promote
Fig. 4. Schematic of typical cell transplantation strategies. First, cells are harvested from a tissue sample from a patient. The cells are then
selected and cultured in vitro. Subsequently, cells may be directly expanded to generate a sufficient population or may be genetically
modified to produce a desired growth factor before expansion. The cells are then seeded onto the polymer matrix and implanted into the
defect site. The unaltered or genetically modified cells secrete growth factor for tissue regeneration.
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wound healing (56). For bone tissue engineering, mesenchy-
mal stem cells have been engineered to express BMP-2 (53)
or BMP-7 (57) and delivered in a polymeric scaffold for stable
production of the proteins. Both endothelial precursors (58)
and primary skeletal muscle cells (59) expressing VEGF have
been used in therapeutic angiogenesis, resulting in growth
factor production for neovascularization. Multiple growth
factor delivery may also be achieved through genetic modifi-
cation; for example, by modifying muscle-derived stem cells
to express VEGF and BMP-4 (60) or modifying cultured der-
mal fibroblasts to express PDGF and VEGF (61). Expression
of a non-native growth factor gene can also alter cell fate
toward a desired fate, as demonstrated by BMP-7 transduced
fibroblasts that were converted into osteoblastic cells (62).
CONCLUSIONS AND FUTURE DIRECTIONS
Growth factor delivery is clearly a therapeutically impor-
tant approach in tissue engineering and will become increas-
ingly powerful as appropriate delivery parameters and factor
specificity are defined. Growth factor therapies show tremen-
dous potential in numerous applications, including wound
healing, bone regeneration, and angiogenesis. Sophisticated
growth factor delivery systems are a major focus of research
in this area, regardless of whether it is the protein itself being
delivered, genes expressing the protein, or cells secreting the
factor. Strategies to deliver growth factors need to exert con-
trol over the complex, integrated networks that define tissue
formation, and may need to be responsive to the changing
dynamics of the network. Pharmaceutical scientists will play a
key role in the future development of growth factor delivery
systems used to regenerate damaged or injured tissue.
A limitation of current strategies for growth factor de-
livery is their focus on the delivery of single growth factors.
However, it is clear that often multiple growth factors work in
concert in a highly regulated network to promote the regen-
eration of tissues. Although delivery of a single growth factor
may be insufficient to promote complete regeneration of tis-
sue structures, the antagonistic roles of multiple factors may
necessitate temporal control over growth factor presentation.
The development of polymeric drug delivery systems capable
of releasing multiple growth factors with distinct release pro-
files may be required to address the more complex require-
ments for regenerating functional tissues. Such a system was
recently described (40), and the utility of this system was
tested in the context of angiogenesis. The initial delivery of
VEGF, followed by a sustained release of PDGF, led to not
only the formation but also maturation of blood vessels. Mul-
tiple growth factor delivery in an orchestrated sequence may
also be useful for cellular de-differentiation toward a prolif-
erative state and subsequent redifferentiation toward a ma-
ture cell type. This concept may be crucial to the usage of
stem cells in tissue engineering, as it may be necessary to first
induce competence toward a fate with exposure to a primary
growth factor that subsequently leads to expression of a re-
ceptor for a secondary growth factor needed for differentia-
tion and maturation.
The spatial patterning of growth factors may also be a
critical issue in tissue regeneration because natural partition-
ing of biologic signals occurs during embryonic development.
Mimicking of biologic patterning may be especially useful to
control tissue development processes such as neovasculariza-
tion, where undirected or uncontrolled growth can lead to
pathologic effects, i.e., tumor metastasis. Techniques devel-
oped for microarray patterning and photolithography, and
micro-electro-mechanical systems may be useful to pattern
growth factors to create gradients. This approach may be
valuable in the generation of complex networks of temporally
and spatially controlled growth factor delivery and to mimic
the micro- and nano-topography of natural ECM.
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